Drug Trial Radar · NCT05580562
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
Last checked: Nov 19, 2026Latest source record: Apr 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
510
Planned (sponsor's estimate)
Start
Jan 23, 2023
Primary completion
Jun 2028
Study completion Jun 2028
Sponsor
- Lead sponsor
- Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
- Sponsor type
- Industry
- Collaborators
- Chimerix, Inc.
- First posted
- Oct 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with dordaviprone (ONC201) following frontline radiotherapy will extend overall survival and progression-free survival in this population. Eligible participants will have histologically diagnosed H3 K27M-mutant diffuse glioma and have completed standard frontline radiotherapy.
Conditions
- H3 K27M
- Glioma
Interventions
Dordaviprone (ONC201)Drug
Participants ≥ 52.5 kg will receive 625 mg of dordaviprone (5 × 125-mg capsules) dosing days; participants \< 52.5 kg will receive a dose (and corresponding number of capsules) scaled by body weight and rounded to 125-mg increments.
Dordaviprone (ONC201) + PlaceboDrug
Participants ≥ 52.5 kg will receive 625 mg of dordaviprone (5 × 125-mg capsules) or matching placebo on dosing days; participants \< 52.5 kg will receive a dose (and corresponding number of capsules) scaled by body weight and rounded to 125-mg increments
PlaceboOther
Participants will receive placebo (same number of capsules as the dordaviprone dose) on dosing days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival (OS)Time frame: From date of randomization until date of death from any cause, assessed up to approximately 44 months
Locations
162 sites in 18 countries. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center
Phoenix, Arizona · Completed
Barrow Neurological Institute
Phoenix, Arizona · Active not recruiting
Phoenix Childrens Hospital
Phoenix, Arizona · Completed
Mayo Clinic Arizona
Phoenix, Arizona · Completed
UC San Diego Moores Cancer Center
La Jolla, California · Active not recruiting
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California · Completed
UCLA University of California Los Angeles
Los Angeles, California · Completed
Children's Hospital of Orange County
Orange, California · Completed
University of California Irvine
Orange, California · Active not recruiting
UCSF Benioff Children's Hospital
San Francisco, California · Active not recruiting
University of California San Francisco
San Francisco, California · Active not recruiting
Providence Saint John's Cancer Institute
Santa Monica, California · Active not recruiting
Stanford Cancer Center
Stanford, California · Completed
Yale University
New Haven, Connecticut · Active not recruiting
MedStar Georgetown University Hospital
Washington D.C., District of Columbia · Completed
Mayo Clinic Jacksonville
Jacksonville, Florida · Active not recruiting
Miami Cancer Institute
Miami, Florida · Active not recruiting
St Joseph's Children's Hospital of Tampa
Tampa, Florida · Completed
Moffitt Cancer Center
Tampa, Florida · Active not recruiting
Cleveland Clinic Florida
Weston, Florida · Completed
Children's Healthcare of Atlanta
Atlanta, Georgia · Completed
Kapi'olani Medical Center for Women and Children
Honolulu, Hawaii · Completed
Feinberg School of Medicine Northwestern University
Chicago, Illinois · Active not recruiting
Indiana University School of Medicine - Indianapolis
Indianapolis, Indiana · Active not recruiting
University of Iowa Hospitals & Clinics
Iowa City, Iowa · Active not recruiting
Norton Healthcare
Louisville, Kentucky · Active not recruiting
Ochsner Medical Center - New Orleans
New Orleans, Louisiana · Completed
University of Maryland School of Medicine
Baltimore, Maryland · Completed
Massachusetts General Hospital Cancer Center
Boston, Massachusetts · Active not recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Active not recruiting
University of Michigan Hospital
Ann Arbor, Michigan · Active not recruiting
University of Minnesota
Minneapolis, Minnesota · Active not recruiting
Mayo Clinic - Cancer Center - Rochester
Rochester, Minnesota · Active not recruiting
Washington University School of Medicine/St. Louis Children's Hospital
St Louis, Missouri · Active not recruiting
Benefis Hospital Sletten Cancer Institute
Great Falls, Montana · Withdrawn
University of Nebraska Medical Center
Omaha, Nebraska · Completed
Jersey Shore University Medical Center
Neptune City, New Jersey · Active not recruiting
Overlook Medical Center
Summit, New Jersey · Active not recruiting
Albany Medical Center
Albany, New York · Completed
Children's Hospital at Montefiore Medical Center
New York, New York · Completed
Showing 40 of 162 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.